文献速递母胎医学

美国胎儿畸形产前外显子组测序可及性:一项定性景观分析

Access to prenatal exome sequencing for fetal malformations: A qualitative landscape analysis in the US.
PubMed 文献 · Prenat Diagn · 2023-09-26

该研究通过两个焦点小组讨论和六次访谈,共纳入来自美国学术中心和社区诊所的13名临床医生(11名遗传咨询师、2名母胎医学/遗传学家),了解其对产前外显子组测序(ES)效用及公平可及性的看法。参与者强烈支持对胎儿结构异常妊娠进行产前ES诊断检测,认为成本与保险覆盖是主要可及性障碍,研究是学术中心获取ES的主要途径。

要点

  • 参与者强烈支持对胎儿结构异常妊娠进行产前外显子组测序诊断检测。
  • 成本与保险覆盖是产前外显子组测序的主要可及性障碍。
  • 研究是学术中心获取产前外显子组测序的主要途径。

核心结论

  • 进一步整合更多关键利益相关者的观点对于理解临床效用、制定解决可及性障碍的政策与实践、以及确保公平提供产前诊断检测十分重要。

研究设计与样本

  • 研究采用两个焦点小组讨论和六次访谈的定性方法,共纳入来自美国学术中心和社区诊所的13名临床医生(11名遗传咨询师、2名母胎医学/遗传学家)。

主要发现

  • 参与者强烈支持对胎儿结构异常妊娠进行产前外显子组测序诊断检测。
  • 参与者强调产前外显子组测序的价值在于提供妊娠前、中、后的连续照护机会,而不仅仅是为流产决策提供信息。
  • 成本与检测的保险覆盖是主要可及性障碍。
  • 研究是学术中心获取产前外显子组测序的主要途径。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is increasing evidence supporting the clinical utility of next generation sequencing for identifying fetal genetic disorders. However, there are limited data on the demand for and accessibility of these tests, as well as payer coverage in the prenatal context. We sought to identify clinician perspectives on the utility of prenatal exome sequencing (ES) and on equitable access to genomic technologies for the care of pregnancies complicated by fetal structural anomalies. METHOD: We conducted two focus group discussions and six interviews with a total of 13 clinicians (11 genetic counselors; 2 Maternal Fetal Medicine/Geneticists) from U.S. academic centers and community clinics. RESULTS: Participants strongly supported ES for prenatal diagnostic testing in pregnancies with fetal structural anomalies. Participants emphasized the value of prenatal ES as an opportunity for a continuum of care before, during, and after a pregnancy, not solely as informing decisions about abortions. Cost and coverage of the test was the main access barrier, and research was the main pathway to access ES in academic centers. CONCLUSION: Further integrating the perspectives of additional key stakeholders are important for understanding clinical utility, developing policies and practices to address access barriers, and assuring equitable provision of prenatal diagnostic testing.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Sahin-Hodoglugil NN, Lianoglou BR, Ackerman S, et al. Access to prenatal exome sequencing for fetal malformations: A qualitative landscape analysis in the US. Prenat Diagn. 2023. PMID: 37752660. doi:10.1002/pd.6444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。